Clinical Trial Update: Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial [Phase 3]

View source ↗

Summary

A Phase 3 trial (ASPIRE) is testing whether adding docetaxel to hormonal therapy and apalutamide improves outcomes in men with metastatic castration-sensitive p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLEADA (apalutamide)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Status: RECRUITING